Details

Autor(en) / Beteiligte

• Boulware, David R
• Murray, Thomas A
• Proper, Jennifer L
• Tignanelli, Christopher J
• Buse, John B
• Liebovitz, David M
• Nicklas, Jacinda M
• Cohen, Kenneth
• Puskarich, Michael A
• Belani, Hrishikesh K
• Siegel, Lianne K
• Klatt, Nichole R
• Odde, David J
• Karger, Amy B
• Ingraham, Nicholas E
• Hartman, Katrina M
• Rao, Via
• Hagen, Aubrey A
• Patel, Barkha
• Fenno, Sarah L
• Avula, Nandini
• Reddy, Neha V
• Erickson, Spencer M
• Lindberg, Sarah
• Fricton, Regina
• Lee, Samuel
• Zaman, Adnin
• Saveraid, Hanna G
• Tordsen, Walker J
• Pullen, Matthew F
• Sherwood, Nancy E
• Huling, Jared D
• Bramante, Carolyn T

Titel

Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination and Booster on Coronavirus Disease 2019 (COVID-19) Symptom Severity Over Time in the COVID-OUT Trial

Ist Teil von

• Clinical infectious diseases, 2023-02, Vol.76 (3), p.e1-e9

Ort / Verlag

United States

Erscheinungsjahr

2023

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination has decreasing protection from acquiring any infection with emergence of new variants; however, vaccination continues to protect against progression to severe coronavirus disease 2019 (COVID-19). The impact of vaccination status on symptoms over time is less clear. Within a randomized trial on early outpatient COVID-19 therapy testing metformin, ivermectin, and/or fluvoxamine, participants recorded symptoms daily for 14 days. Participants were given a paper symptom diary allowing them to circle the severity of 14 symptoms as none (0), mild (1), moderate (2), or severe (3). This is a secondary analysis of clinical trial data on symptom severity over time using generalized estimating equations comparing those unvaccinated, SARS-CoV-2 vaccinated with primary vaccine series only, or vaccine-boosted. The parent clinical trial prospectively enrolled 1323 participants, of whom 1062 (80%) prospectively recorded some daily symptom data. Of these, 480 (45%) were unvaccinated, 530 (50%) were vaccinated with primary series only, and 52 (5%) vaccine-boosted. Overall symptom severity was least for the vaccine-boosted group and most severe for unvaccinated at baseline and over the 14 days (P < .001). Individual symptoms were least severe in the vaccine-boosted group including cough, chills, fever, nausea, fatigue, myalgia, headache, and diarrhea, as well as smell and taste abnormalities. Results were consistent over Delta and Omicron variant time periods. SARS-CoV-2 vaccine-boosted participants had the least severe symptoms during COVID-19, which abated the quickest over time. Clinical Trial Registration. NCT04510194.